Literature DB >> 23558869

Risk factors for bleeding complications in patients undergoing transcatheter aortic valve implantation (TAVI).

Janina Stępińska1, Katarzyna Czerwińska, Adam Witkowski, Maciej Dąbrowski, Zbigniew Chmielak, Krzysztof Kuśmierski, Tomasz Hryniewiecki, Marcin Demkow.   

Abstract

BACKGROUND: The risk of bleedings in transcatheter aortic valve implantation (TAVI) patients increases due to age and concomitant diseases. The aim of the study was to assess the risk of bleedings, their influence on early prognosis of TAVI patients and utility of the TIMI and GUSTO scales in the evaluation of bleeding and in prediction of blood transfusion.
METHODS: This was a single center study of in-hospital bleedings in 56 consecutive TAVI patients. Bleedings were classified according to the GUSTO and TIMI scales. HASBLED's scale risk factors, diabetes mellitus, female sex, the route of bioprosthesis implantation and inhospital antithrombotic treatment were analyzed. Statistical analysis consisted of c2, Fisher's exact, Wilcoxon tests and logistic regression analysis.
RESULTS: Serious bleedings occurred in 35 (62.5%) patients. There was no significant correlation with HASBLED score. History of anemia was a significant predictor of bleeding in GUSTO (p = 0.0013) and TIMI (p = 0.048) scales. No bleedings in patients receiving vitamin K antagonists (VKA) pre- and VKA plus clopidogrel post intervention were observed. Patients with bleedings according to the GUSTO scale more often required blood tranfusion than in TIMI scale (p = 0.03).
CONCLUSIONS: History of anemia is the strongest predictor of serious bleedings. VKA before and VKA with clopidogrel after TAVI are safer than dual antiplatelet or triple therapy. The TIMI and GUSTO scales can adequately classify bleeding after TAVI, however the GUSTO better predicts transfusions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23558869     DOI: 10.5603/CJ.2013.0024

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  4 in total

Review 1.  Access site bleeding after transcatheter aortic valve implantation.

Authors:  Abhishek Sharma; Armin Arbab-Zadeh; Divyanshu Dubey; Jacob Shani; Jason Lazar; Robert Frankel
Journal:  J Thromb Thrombolysis       Date:  2013-05       Impact factor: 2.300

2.  Antithrombotic therapy in patients undergoing TAVI with concurrent atrial fibrillation. One center experience.

Authors:  Manolis Vavuranakis; Konstantinos Kalogeras; Dimitrios Vrachatis; Maria Kariori; Carmen Moldovan; Evelina Mpei; Maria Lavda; Angelos-Michail Kolokathis; Gerasimos Siasos; Dimitrios Tousoulis
Journal:  J Thromb Thrombolysis       Date:  2015-08       Impact factor: 2.300

3.  Prevalence of blood type A and risk of vascular complications following transcatheter aortic valve implantation.

Authors:  M-T Rofe; Y Shacham; A Steinvi; L Barak; M Hareuveni; S Banai; G Keren; A Finkelstein; H Shmilovich
Journal:  Neth Heart J       Date:  2016-05       Impact factor: 2.380

Review 4.  Antithrombotic therapy in TAVI.

Authors:  Manolis Vavuranakis; Konstantinos Kalogeras; Angelos Michail Kolokathis; Dimitrios Vrachatis; Nikolaos Magkoutis; Gerasimos Siasos; Euaggelos Oikonomou; Maria Kariori; Theodoros Papaioannou; Maria Lavda; Carmen Moldovan; Ourania Katsarou; Dimitrios Tousoulis
Journal:  J Geriatr Cardiol       Date:  2018-01       Impact factor: 3.327

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.